Drug intelligence / Profile preview

ilexgenin A

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Injection

Overview

Ilexgenin A is a **pentacyclic triterpenoid** extracted from *Ilex hainanensis Merr.* It is used in research for its **anti-inflammatory** and **anticancer properties**. Ilexgenin A has shown potential in treating various cancers, including human skin cancer, pulmonary carcinoma, and gastric cancer, by inhibiting tumor cell growth in vitro and in vivo[1][2]. It also exhibits anti-inflammatory effects by reducing inflammatory cytokines and modulating signaling pathways[3]. Additionally, it has been studied for its role in improving non-alcoholic fatty liver disease[7].

Other names: Ilexgenin A

Targets

AMPK (Adenosine monophosphate–activated protein kinase)SREBP-1 / SREBF1 (SREBP-1)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on ilexgenin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ilexgenin A.

Explore the full profile